Cervical cancer screening shouldn't start until 25

February 20, 2013 by Kirsten Mccaffery, Alexandra Barratt & Jane Williams
There’s virtually no difference in cancer incidence between women aged 20-24 years who screened are and those who are not. Credit: Spirit-Fire/Flickr

Women in England, Scotland, Wales and Northern Ireland will all soon be advised to start screening for cervical cancer at 25 years, and those aged between 50 and 64 years to screen every five years rather than every three. And a review of the Australian National Cervical Screening Program is considering whether it should make the same recommendations.

The Australian review is considering evidence on the screening starting age and the interval between Pap smears, as well as different such as Liquid Based Cytology (LBC) and primary HPV testing. It coincides the with major changes in similar programs in the United Kingdom based on recommendations by the UK National Screening Committee (NSC).

The policy change was made in England in 2003 and Northern Ireland in 2010. And following a recent review, the protocol has been recommended for extension to both Scotland and Wales.

The changes are based on evidence that screening women under 25 offers little benefit. In fact, screening this age group arguably causes "more harm than good" with little or no health benefit, and potential physical, psychological, and economic harms. is extremely rare in young women and the efficacy of screening drops as age decreases.

In a large UK population-based study, researchers found evidence that screening women aged 20 to 24 "has little or no impact on cervical cancer" and that there was virtually no difference in between women who were screened within that age range and those who were not.

These findings are supported by a better understanding of the cause and natural history of cervical cancer. (HPV) is the primary cause of cervical cancer and cervical abnormalities detected at screening. HPV infection in young women represents a transient or short-term infection that can be spontaneously cleared by the immune system. It's only persistent infection that causes severe or clinically significant cervical abnormalities and cancer, and it's this kind of HPV infection that is important to detect and treat.

Screening young women results in the detection and over-treatment of transient infections, which would otherwise clear naturally. Detection and treatment of inconsequential disease has important negative consequences for young women, with evidence of psychosocial harm (worry, anxiety, guilt and concerns about infertility and relationships), economic costs (treatment and sick leave) and potential physical harm because the treatment of the cervix is linked to perinatal mortality and adverse pregnancy outcomes.

The UK NSC also highlighted the impact of the HPV vaccine program on reducing infection and cervical abnormalities in young women, suggesting vaccination would further reduce any benefit of screening found in the younger age group.

The policy change is consistent with the International Agency of Research on Cancers (IARC) 2005 review of cervix screening, which states that "organised programs should not include women aged less than 25 years in their target populations". The IARC also recommends a three-year screening interval for women aged 25 to 49 years and five years for women between 50 and 65.

The recommendation for longer screening intervals by both IARC and the UK NSC is based on evidence that the benefit of screening every two years, rather than three, is small. Similarly, screening every three years (rather than five years) from age 50 onwards offers little with a increase in protection of 4% (from 83% five yearly to 87% three yearly), yet a substantial increase in program costs of around 60% to 66%.

In Australia, two-yearly cervical screening begins at 18 or two years after the start of sexual activity, whichever is later. Approximately 450,000 women under 25, and 1.1 million women over 50 were screened in 2008-2009.

Australia has a high-quality and very effective cervical and has taken a leading role in providing HPV vaccination in school-based programs. Cervical cancer incidence and mortality (nine in every 100,000 and two in every 100,000 women aged 20 to 69, respectively) are low by international standards, and the numbers have halved since the introduction of a national organised screening program in 1991.

Continuing this leading role, while minimising unnecessary harm, particularly the over-treatment of , should be a priority.

Nevertheless disparities remain. Cervical cancer incidence and mortality are significantly higher among Aboriginal and Torres Strait Islander women compared to the rest of the Australian population, and are also higher in women living in remote and very remote areas. Women in the highest fifth of the social strata have the lowest cervical cancer incidence and mortality.

The current review offers an opportunity to renew the Australian program to maximise benefit, while minimising harm and redirecting resources in beneficial and cost-effective ways. It's an opportunity to deliver a cervical program that is beneficial, accessible and acceptable to all Australian .

Explore further: Lack of clarity about HPV vaccine and the need for cervical cancer screening

Related Stories

Lack of clarity about HPV vaccine and the need for cervical cancer screening

July 7, 2011
The research will be presented today at the Annual Scientific Meeting of the Society of Academic Primary Care, hosted this year by the Academic Unit of Primary Health Care, University of Bristol.

Cervical cancers rise in young women

November 7, 2011
(Medical Xpress) -- The incidence of cervical cancer in women in their 20s has risen by over 40 per cent between 1992 and 2006 in England, despite the overall incidence of cervical cancer dropping by 30 per cent, according ...

HPV testing in screening program saves 3,500 women from unnecessary tests

September 28, 2011
Testing for the human papillomavirus (HPV) as part of cervical screening reduces the number of women unnecessarily going on for further tests by over a third, new research shows today.

Screening for HPV persistence and cervical cancer risk

September 6, 2011
Women over the age of thirty who test positive for HPV (Human Papillomavirus) should be re-tested two years later as part of cervical cancer screening, according to a study published online TK in the Journal of the National ...

Less frequent pap tests safe for most women, ob/gyn group says

October 22, 2012
(HealthDay)—Most women need testing for cervical cancer only every three to five years, rather than annually, according to the American College of Obstetricians and Gynecologists.

Recommended for you

No dye: Cancer patients' gray hair darkened on immune drugs

July 21, 2017
Cancer patients' gray hair unexpectedly turned youthfully dark while taking novel drugs, and it has doctors scratching their heads.

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.